ClinicalTrials.gg
Drug

Pacritinib clinical trials

Also written SB1518 and Vonjo.

studies test it
50
open now
19
in phase 3
3
first study started
2008

How each study uses pacritinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pacritinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Feb 2022 · VONJO · NDA 208712 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pacritinib
44
Oral JAK2 Inhibitor SB1518
4
937272-79-2
2

Brand

Vonjo
5

Development codes

SB1518
16

Studies by the year they started

50 studies that test it; most in 2026 (10)

Studies that test pacritinib, by start year
YearStudies
20083
20101
20111
20121
20131
20144
20157
20161
20174
20181
20191
20203
20211
20233
20243
20255
202610

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
24
Phase 2
32
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 18 · Other 32

CTI BioPharma (10) · S*BIO (4) · Washington University School of Medicine (4) · National Cancer Institute (NCI) (3) · University of Michigan Rogel Cancer Center (3) · M.D. Anderson Cancer Center (3) · Swedish Orphan Biovitrum (2) · University of Washington (2)

Often tested with

Tested in the same studies.

Azacitidine (4) · Decitabine (2) · Ruxolitinib (2) · Luspatercept (1) · Venetoclax (1) · Selinexor (1) · BTK Inhibitor (1) · Fedratinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 7

Studies that test pacritinib.

Studies

Open first, then newest update. How each study uses pacritinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test pacritinib →

Given beside what is tested · 3 — pacritinib is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call pacritinib · ClinicalTrials.gg INT005890

  • MeSH (NLM) C561234pacritinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) G22N65IL3OPACRITINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2595243One source FDA
  • Wikidata Q3888693pacritinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C78837PacritinibOne source FDA
  • DrugBank DB11697One source Wikidata

Also registered as pacritinib citrate (UNII VJ2PH4NXX7 · RxNorm 2595242).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.